GLUE vs. DCTH

Last updated Apr 1, 2026

Compare and contrast key facts about Monte Rosa Therapeutics, Inc. (GLUE) and Delcath Systems, Inc. (DCTH).

Performance

GLUE vs. DCTH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monte Rosa Therapeutics, Inc. (GLUE) and Delcath Systems, Inc. (DCTH). The values are adjusted to include any dividend payments, if applicable.

GLUE vs. DCTH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GLUE Monte Rosa Therapeutics, Inc.	4.91%	125.94%	22.83%	-25.76%	-62.73%	-3.59%
DCTH Delcath Systems, Inc.	-8.12%	-16.11%	189.42%	15.56%	-53.55%	-29.80%

Fundamentals

EPS GLUE : -$0.72 DCTH : $0.07
PS Ratio GLUE : 7.30 DCTH : 5.60
Total Revenue (TTM) GLUE : $123.67M DCTH : $64.50M
Gross Profit (TTM) GLUE : $118.80M DCTH : $73.43M
EBITDA (TTM) GLUE : -$45.22M DCTH : $1.61M

Returns By Period

In the year-to-date period, GLUE achieves a 4.91% return, which is significantly higher than DCTH's -8.12% return.

GLUE

• 1D: 5.92%
• 1M: -7.32%
• YTD: 4.91%
• 6M: 122.00%
• 1Y: 254.53%
• 3Y*: 28.29%
• 5Y*: —
• 10Y*: —

DCTH

• 1D: 4.39%
• 1M: 4.27%
• YTD: -8.12%
• 6M: -13.67%
• 1Y: -27.10%
• 3Y*: 17.30%
• 5Y*: -5.40%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GLUE vs. DCTH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 96
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 94
GLUE Martin Ratio Rank: 93

DCTH

DCTH Risk / Return Rank: 24
DCTH Sharpe Ratio Rank: 21
DCTH Sortino Ratio Rank: 21
DCTH Omega Ratio Rank: 23
DCTH Calmar Ratio Rank: 24
DCTH Martin Ratio Rank: 29

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GLUE vs. DCTH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and Delcath Systems, Inc. (DCTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GLUE	DCTH	Difference
Sharpe ratio Return per unit of total volatility	2.68	-0.47	+3.14
Sortino ratio Return per unit of downside risk	3.77	-0.39	+4.16
Omega ratio Gain probability vs. loss probability	1.43	0.95	+0.48
Calmar ratio Return relative to maximum drawdown	5.32	-0.54	+5.86
Martin ratio Return relative to average drawdown	12.85	-0.77	+13.62
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GLUE vs. DCTH - Sharpe Ratio Comparison

The current GLUE Sharpe Ratio is 2.68, which is higher than the DCTH Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of GLUE and DCTH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GLUE	DCTH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.68	-0.47	+3.14
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.07	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	-0.45	+0.40

Correlation

The correlation between GLUE and DCTH is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GLUE vs. DCTH - Dividend Comparison

Neither GLUE nor DCTH has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GLUE vs. DCTH - Drawdown Comparison

The maximum GLUE drawdown since its inception was -94.08%, smaller than the maximum DCTH drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for GLUE and DCTH.

Drawdown Indicators

	GLUE	DCTH	Difference
Max Drawdown Largest peak-to-trough decline	-94.08%	-99.96%	+5.88%
Max Drawdown (1Y) Largest decline over 1 year	-41.84%	-54.75%	+12.91%
Max Drawdown (5Y) Largest decline over 5 years	—	-85.10%	—
Current Drawdown Current decline from peak	-61.03%	-99.85%	+38.82%
Average Drawdown Average peak-to-trough decline	-75.32%	-96.38%	+21.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.32%	38.26%	-20.94%

Volatility

GLUE vs. DCTH - Volatility Comparison

Monte Rosa Therapeutics, Inc. (GLUE) has a higher volatility of 14.31% compared to Delcath Systems, Inc. (DCTH) at 12.83%. This indicates that GLUE's price experiences larger fluctuations and is considered to be riskier than DCTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GLUE	DCTH	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.31%	12.83%	+1.48%
Volatility (6M) Calculated over the trailing 6-month period	63.89%	36.46%	+27.43%
Volatility (1Y) Calculated over the trailing 1-year period	96.16%	58.48%	+37.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	102.69%	74.15%	+28.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	102.69%	111.20%	-8.51%

Financials